Q-omics provides the consensus-scored CSAG4 profile across patient tissues and cancer cell-line models. CSAG4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CSAG4 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, CSAG4 RNA expression shows 5,324 significant pathway-activity associations, with the highest sampling consensus in SKCM. Together, these results highlight MESO, HNSC, and SKCM as cancer lineages where CSAG4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSAG4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSAG4 survival associations across molecular data types. CSAG4 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSAG4 RNA expression–survival associations across cancer types. High CSAG4 expression shows unfavorable associations in MESO, KIRC, COAD, LIHC, KIRP and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CSAG4 RNA expression.
This table summarizes CSAG4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CSAG4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSAG4 shows higher tumor expression in HNSC, LIHC, BRCA, LUSC, LUAD and STAD. The HNSC box plot shows higher CSAG4 RNA expression in tumor versus normal tissue (log2 FC = +0.330, t-test p = .001).
This table shows molecular features associated with CSAG4 in patient tissues and cancer cell lines. In patient samples, CSAG4 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
